In the induction study AT-IR subgroup, 85.7% of patients had prior exposure to anti-TNF therapy, 56.7% had prior exposure to vedolizumab, and 19.1% had prior exposure to JAK inhibitors (Table 1). The gene discussed is TNF; the disease is ataxia telangiectasia.